Similar articles

• [Acute severe myositis due to bezafibrate treatment].

  Yeshurun D, Dakak N, Khoury K, Daher E. Yeshurun D, et al. Harefuah. 1989 Mar 1;116(5):261-3. Harefuah. 1989. PMID: 2722079 Hebrew.
• [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].

  Bolzano K, Krempler F, Schellenberg B, Schlierf G. Bolzano K, et al. Acta Med Austriaca. 1979;6(3):90-4. Acta Med Austriaca. 1979. PMID: 547652 German.
• [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV].

  Chwistecki K, Mrukowicz M, Kopel E. Chwistecki K, et al. Przegl Lek. 1984;41(9):581-6. Przegl Lek. 1984. PMID: 6393227 Clinical Trial. Polish. No abstract available.
• Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.

  Schumacher M, Eber B, Silberbauer K, Breier C, Stühlinger W, Schmidt P, Gaul G, Klein W. Schumacher M, et al. Acta Med Austriaca. 1992;19(5):140-4. Acta Med Austriaca. 1992. PMID: 1298143 Clinical Trial.
• [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].

  Noseda G, Fragiacomo C, Weidmann P, Bachmann C. Noseda G, et al. Schweiz Med Wochenschr. 1980 Dec 6;110(49):1875-7. Schweiz Med Wochenschr. 1980. PMID: 7455660 German.